Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury

The Walter Reed Army Institute of Research has commenced a study assessing the effectiveness of Nyrada's (ASX:NYR) NYR-BI03 in traumatic brain injury, according to a Tuesday filing with the Australian

MT NewswiresApr 30 11:58

Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program

Drug developer Nyrada (ASX:NYR) posted its quarterly activities report for the period ending March 31, which shows the company completed a stroke study in its brain injury program NYR-BI03, according

MT NewswiresApr 10 11:35

Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate

Nyrada (ASX:NYR) has begun its good laboratory practice preclinical study to test NYR-BI03, the company's drug candidate for treating brain injury, according to an Australian bourse filing on Thursday

MT NewswiresMar 28 09:52

Nyrada Raises AU$1.8 Million via Placement

Drug development firm Nyrada (ASX:NYR) raised a total of AU$1.755 million of new equity capital, before costs, from new and existing professional and sophisticated investors, according to a Wednesday

MT NewswiresMar 6 12:08

Significant Results for Nyrada's Brain Injury Treatment

Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results for using NYR-B103 to treat brain injuries.Paul Sanger: I'm Paul Sanger for the Finance News Network, and today I'm talking to Nyrada Inc (A

sharecafeMar 1 06:50

Nyrada NYR-BI03 Trial Success Heralds Breakthrough in Stroke and Brain Injury Treatment

Drug discovery and development company Nyrada (ASX: NYR) has announced positive results from a pre-clinical study evaluating lead candidate NYR-BI03 in the prevention of secondary brain injury.

Small CapsFeb 28 10:32